Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial.
Ann Oncol
; 34(8): 660-669, 2023 08.
Article
in En
| MEDLINE
| ID: mdl-37201751
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Clinical_trials
Aspects:
Patient_preference
Limits:
Female
/
Humans
/
Middle aged
Language:
En
Journal:
Ann Oncol
Year:
2023
Document type:
Article